Main information

  • Trade name:
  • Static magnetic bedding
  • Class:
  • Class 1
  • Medicine domain:
  • Humans
  • Medicine type:
  • Medical device



  • Available in:
  • Static magnetic bedding
  • Language:
  • English

Other information


  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 222810
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:


The Natural Group Pty Ltd - Static magnetic bedding

ARTG entry for

Medical Device Included Class 1


The Natural Group Pty Ltd

Postal Address

PO Box 364,ARUNDEL, QLD, 4214


ARTG Start Date


Product category

Medical Device Class 1



Approval area

Medical Devices


- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry. Refer Part 4-5,

Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.2 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations

2002 for relevant information.

- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal

offence; and civil penalties may apply.




The Natural Group Pty Ltd

Suites 4-5/13-15 Ereton Drive




1. Static magnetic bedding

Product Type

Single Device Product

Effective date



44748 Static magnetic bedding

Intended purpose

Some research suggests that Static Magnetic Fields, when properly located and applied, have the

potential to temporarily:

?provide relief from minor pains, inflammation, aching or tenderness from ailments like arthritis, etc;

?relieve muscular stiffness and soreness; and

?assist with peripheral blood circulation.

The weak magnetic flux generated by the static magnets in The Natural bioMagnetic have the potential to

help with muscle relaxation and the temporary relief of pain and inflammation while sleeping or resting,

inducing better sleep and a feeling of greater wellbeing upon waking.

Specific Conditions

No Specific Conditions included on Record

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 1 of

Produced at 09.11.2017 at 07:48:06 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information


FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

FDA - U.S. Food and Drug Administration


EMA's new assessment of the HPV vaccine: The benefits outweigh the risks

EMA's new assessment of the HPV vaccine: The benefits outweigh the risks

A causal relationship between the dizziness and fatigue syndrome, Postural Orthostatic Tachycardia Syndrome (POTS) and Gardasil can neither be confirmed nor denied. The EU's group of pharmacovigilance experts have made a new assessment of the vaccine and still consider it to be safe.

Danish Medicines Agency

There are no news related to this product.